Cantor Fitzgerald Forecasts Zura Bio FY2025 Earnings

Zura Bio Limited (NASDAQ:ZURA) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Zura Bio in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($0.40) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share.

A number of other equities analysts have also recently weighed in on the company. HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a report on Tuesday, December 24th. Chardan Capital cut their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Leerink Partners initiated coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 target price on the stock. Finally, Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $15.80.

Zura Bio Price Performance

Shares of ZURA opened at $1.79 on Thursday. Zura Bio has a 1-year low of $1.74 and a 1-year high of $6.35. The firm has a 50 day simple moving average of $2.52 and a 200-day simple moving average of $3.47.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.12).

Institutional Investors Weigh In On Zura Bio

Several institutional investors have recently bought and sold shares of ZURA. Braidwell LP purchased a new position in shares of Zura Bio in the 3rd quarter valued at $10,040,000. Point72 Asset Management L.P. acquired a new stake in Zura Bio in the 2nd quarter valued at $8,446,000. Armistice Capital LLC raised its position in Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after purchasing an additional 876,000 shares during the period. Sphera Funds Management LTD. acquired a new position in shares of Zura Bio during the third quarter worth about $2,999,000. Finally, Geode Capital Management LLC boosted its position in shares of Zura Bio by 70.6% in the third quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock worth $3,706,000 after buying an additional 377,545 shares during the period. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Parvinder Thiara sold 1,001,633 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 22.10% of the stock is currently owned by insiders.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.